Glucocorticoid therapy and memory function: lessons learned from basic research.

Benno Roozendaal; Dominique J F de Quervain

doi:10.1212/01.wnl.0000151711.27744.95

Home/Archive/PubMed

PubMed · 15668410

Glucocorticoid therapy and memory function: lessons learned from basic research.

Benno Roozendaal·Dominique J F de Quervain

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Anti-Inflammatory Agents Glucocorticoids Hippocampus Humans Learning Memory Memory Disorders Mental Recall Multiple Sclerosis Optic Neuritis Stress, Physiological Comment Editorial

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Benno Roozendaal, Dominique J F de Quervain. 2005-01-25. Glucocorticoid therapy and memory function: lessons learned from basic research.. https://doi.org/10.1212/01.wnl.0000151711.27744.95

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Activated protein C and sepsis.

Protein C is a plasma protease that when activated plays a central role in modulating the function of the vascular endothelium and its interface with the innate immune system. A recombinant form of human activated protein C (APC), drotrecogin alfa (activated), has shown efficacy in a number of preclinical models of thrombosis and ischemia and reduces mortality in patients that have a high risk of dying from severe sepsis. Studies have begun to elucidate the mechanism for the multifunctional role of APC in modulating not only coagulation, but also inflammation and apoptotic processes. From gene profiling to pharmacology studies, drotrecogin alfa (activated) appears to directly modulate endothelial dysfunction by blocking cytokine signaling, functional cell adhesion expression, vascular permeability and preventing the induction of apoptosis. Moreover, APC, via endothelial protein C receptor/protease activated receptor-1 mediated mechanisms, also appears to directly modulate leukocyte migration and adhesion. The ability of APC to suppress pro-inflammatory pathways and enhance cellular survival suggests that APC has a role in the adaptive response at the vessel wall, in which it protects the wall from vascular insult and prolongs endothelial, cellular, and organ survival. The emerging data further suggest that APC effectively modulates the complex changes that occur during multi-system activation and dysfunction in sepsis.

Anti-Inflammatory Agents↗

PubMed2006

HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL).

BACKGROUND: Dexamethasone is increasingly used as the steroid of choice in trials for standard risk children with acute lymphoblastic leukemia (ALL). Improvements in event-free survival (EFS) have been attributed to lower CNS relapse rates, However, there are concerns that dexamethasone may be more toxic than previous conventional therapy with prednisone. Such toxicity raises questions about the implications for child neuropsychological function and HRQOL. Patients participating in the UK ALL 99/01 trial were randomized to receive dexamethasone or prednisone as their steroid in induction and maintenance chemotherapy. We compared the HRQOL and behavior in children randomized to receive both these agents. PROCEDURE: Standardized questionnaires to assess parent and child HRQOL at 3-6 months after diagnosis (T1) and 1 year later (T2) completed by mothers in family homes. Forty-five mothers of a child with ALL (32 male, 13 female; average age at T1, 7 years 3 months; at T2, 8 years 3 months) completed HRQOL questionnaires. RESULTS: For the total group, child HRQOL scores improved and behavior problems decreased significantly from T1 to T2. Comparison of HRQOL scores between the 17 children randomized to dexamethasone and 28 children randomized to prednisone showed no significant differences. The rate of improvement in HRQOL from T1 to T2 did not differ between children randomized to dexamethasone or prednisone. CONCLUSIONS: Dexamethasone is increasingly used in the treatment of ALL and has been linked with improved survival rates. Long-term use of dexamethasone raises questions about neuropsychologic toxicity. Although HRQOL increased significantly over the year for all children, the extent of this increase did not differ by chemotherapy. These results should contribute to lessened concerns about use of dexamethasone in the treatment of ALL.

Anti-Inflammatory Agents↗

PubMed2006

[Intravitreal triamcinolone acetonide Complication of infectious and sterile endophthalmitis].

PURPOSE: Intravitreal triamcinolone acetonide (TA), applied as treatment for various edematous and neovascular ocular diseases, was analyzed for infectious or sterile endophthalmitis and pseudoendophthalmitis. METHODS: In a prospective interventional study, 645 eyes were treated with approximately 20 mg intravitreal TA. The removal of the vehicle and the intravitreal injection were performed under sterile conditions. A total of 97 eyes received a second TA injection, 13 a third, 1 a fourth, 2 a fifth, and 1 a sixth injection. The mean follow-up was 7.5 months (median: 5.7 months). RESULTS: In the 1st week after 759 TA injections, 758 resulted in no hypopyon or Tyndall phenomenon >2(+), but in one eye a pseudoendophthalmitis with hypopyon was present. Anterior chamber lavage demonstrated TA crystals, and the culture was negative. In the 2nd week, one patient developed infectious endophthalmitis after a fall had caused ocular perforation. CONCLUSIONS: Intravitreal TA injections (approximately 20 mg) harbor a low risk of infectious or sterile endophthalmitis and pseudoendophthalmitis, if the injection and vehicle removal are performed under sterile conditions.

Anti-Inflammatory Agents↗